1. Home
  2. QLYS vs ERAS Comparison

QLYS vs ERAS Comparison

Compare QLYS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qualys Inc.

QLYS

Qualys Inc.

SELL

Current Price

$190.12

Market Cap

7.0B

Sector

Technology

ML Signal

SELL

Logo Erasca Inc.

ERAS

Erasca Inc.

SELL

Current Price

$14.73

Market Cap

6.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
QLYS
ERAS
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.3B
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
QLYS
ERAS
Price
$190.12
$14.73
Analyst Decision
Hold
Buy
Analyst Count
22
9
Target Price
★ $181.03
$24.11
AVG Volume (30 Days)
600.4K
★ 4.9M
Earning Date
11-03-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
16.99
★ 36.23
EPS
★ 2.91
N/A
Revenue
★ $321,607,000.00
N/A
Revenue This Year
$9.85
N/A
Revenue Next Year
$8.22
N/A
P/E Ratio
$65.01
★ N/A
Revenue Growth
★ 15.32
N/A
52 Week Low
$74.51
$2.11
52 Week High
$206.25
$24.28

Technical Indicators

Market Signals
Indicator
QLYS
ERAS
Relative Strength Index (RSI) 53.37 45.11
Support Level $128.98 $13.56
Resistance Level $191.57 $15.03
Average True Range (ATR) 8.40 0.85
MACD -0.22 0.13
Stochastic Oscillator 59.65 41.32

Price Performance

Historical Comparison
QLYS
ERAS

About QLYS Qualys Inc.

Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: